THÔNG TIN TÀI LIỆU
Thông tin cơ bản
Định dạng | |
---|---|
Số trang | 43 |
Dung lượng | 313 KB |
Nội dung
Ngày đăng: 28/10/2020, 07:49
Nguồn tham khảo
Tài liệu tham khảo | Loại | Chi tiết |
---|---|---|
11. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1–1315. (quiz CE1–4) | Khác | |
12. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999;76:149–158 | Khác | |
13. Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, et al.Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000;32:388–393 | Khác | |
14. Ergunay K, Sener B, Alp A, Karakaya J, Hascelik G. Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 2011;70:486–491 | Khác | |
15. M Omata, T Kanda, M L Yu, et al., APASL consensus statements and management algorithms for hepatitis C virus infection, Hepatol Int, DOI 10.1007/s12072-012-9342-y | Khác | |
16. Van H P, Huyen D P Nguyen, Phat T H, et al. Very high prevalence of Hepatitis C virus genotype 6 variants in Southern Vietnam: Large scale survey based on sequence determination. Jpn.J.Infect.Dis. 2011,64:537- 539 | Khác | |
18. P H Phiệt, Đ T H An, L T T Vi . Ở phía nam Việt nam, phần lớn HCV- GT1 xác định bằng vùng 5’UTR thực ra là thuộc HCV-GT6 khi xác định vùng NS5B. Số liệu từ Phòng khám Gan Mật Sài gòn (SLC). Tạp chí Gan Mật Việt nam 2012;20:7-12 | Khác | |
19. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884–1893 20. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P.Shortened treatment duration in treatment-nạve genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010;52:25–31 | Khác | |
21. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-nạve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260–1269 | Khác | |
23. AASLD practice guidelines: Diagnosis, Management and Treatment of Hepatitis C: An Update, Hepatology 2009;49(4):1335-1374 | Khác | |
24. Paggi S, Colli A, Fraquelli M, Vigano M, Del Poggio P, Facciotto C, et al. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal–external validation. J Hepatol 2008;49:564–571 | Khác |
TRÍCH ĐOẠN
TÀI LIỆU CÙNG NGƯỜI DÙNG
TÀI LIỆU LIÊN QUAN